中文Vientiane, Laos - August 01, 2023 - Big Bear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative treatments for cancer, announced today that two products has been approved by the Lao Ministry of Health.
Approved drugs are:
Ibrutinib: Sold under the brand name ILUDX. Ibrutinib is the first Bruton's tyrosine kinase (BTK) inhibitor that can form a covalent bond with the center of the BTK active site, thereby inhibiting BTK activity. On November 13, 2013, it was approved for marketing by FDA.
Erdafitinib: Sold under the brand name ERDAD. Erdafitinib is a FGFR1~4 tyrosine kinase inhibitor with antitumor activity. It is the first oral FGFR inhibitor approved by the FDA. In April 2019, the FDA granted accelerated approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic bladder cancer with FGFR3 or FGFR2 mutations who have progressed after platinum-based chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy of patients.
About Big Bear Pharma
Big Bear Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer. The company has a diverse pipeline of anti-cancer targeted drugs that address various molecular pathways and mechanisms of action. Big Bear Pharma aims to improve the lives of patients with cancer by providing them with more options, better outcomes and lower costs.
Forward-Looking Statements
To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.